Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264097 | 0.78 | CYP3A4 (0.42) | PRMT5WDR77 | |
| SCHEMBL264674 | 0.77 | CYP3A4 (0.37) | PRMT5WDR77 | |
| SCHEMBL11997792 | 0.75 | CYP3A4 (0.37) | PRMT5WDR77 | |
| SCHEMBL2786003 | 0.75 | NPC1 (0.39) | PRMT5WDR77DOT1L | |
| SCHEMBL3485906 | 0.74 | ADORA2A (0.43) | DOT1L | |
| SCHEMBL11997791 | 0.74 | CYP3A4 (0.36) | PRMT5WDR77 | |
| SCHEMBL2512961 | 0.72 | PRMT5 (0.48) | PRMT5WDR77DOT1L | |
| SCHEMBL24939894 | 0.70 | ADORA1 (0.49) | — | |
| SCHEMBL264092 | 0.70 | ADORA2A (0.48) | DOT1L | |
| SCHEMBL13843324 | 0.70 | ADORA2A (0.48) | DOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | claimed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | PRMT5 825/4885WDR77 959/4885DOT1L 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.